- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05667324
Septorhinoplasty Post-operative Pain Control With SPG Nerve Block
April 6, 2026 updated by: University of Florida
Post-operative Pain Control With Sphenopalantine Ganglion Nerve Block in Septorhinoplasty Patients
Maxillary nerve blocks have been shown to significantly reduce post-operative pain and analgesic intake during the 24-hour period following sinus surgery.
This randomized, double-blinded, placebo-controlled study will investigate blocks of the sphenopalatine ganglion using a suprazygomatic approach during septorhinoplasty surgery.
It is the investigator's hypothesis that this technique will result in decreased post-operative pain and opioid use, and the morbidity associated with it.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- UF Health of University of Florida
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient presenting for open or endoscopic septorhinoplasty
- Age 18-80
- Normal oral food and water intake before surgery
- ASA physical classification 1-3
Exclusion Criteria:
- Refusal to consent
- Patients without a cellular phone or who are unable to accept text messages
- Allergy to opioid narcotics
- ASA physical classification of 4 or higher
- Patient requires other surgery in addition to septorhinoplasty
- Age > 80 or <18
- Any underlying chronic pain condition or ongoing opioid use over the preceding 3 months
- Presence of any other factor which, at the discretion of any member of the study team, makes the patient a poor candidate for block placement.
- Presence of any other factor which, at the discretion of any member of the study team, makes the patient a poor candidate for research participation.
- Pregnant women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group 1: Ropivacaine plus Dexamethasone
The group 1 injection procedure will be performed as follows: after preparation of the skin using appropriate skin preparation solution and using aseptic technique, a small-gauge spinal needle will be advanced into the pterygopalatine fossa under ultrasound guidance.
Once the needle is properly positioned, 0.5% ropivacaine will be administered at a dose of 20 mg plus 4 mg dexamethasone and the needle will be removed.
This procedure will be performed bilaterally
|
A single injection into the pterygopalatine fossa bilaterally of 0.5% ropivacaine at a dose of 20 mg (each side)
Plus 4 mg dexamethasone
|
|
Active Comparator: Group 2: Placebo plus Dexamethasone
In group 2 the same procedure will be performed, but the injectate will consist of 5 mL of a balanced crystalloid intravenous solution (4 ml of normal saline) plus 4 mg dexamethasone (each side).
This procedure will be performed bilaterally.
|
Plus 4 mg dexamethasone
A single injection into the pterygopalatine fossa bilaterally of a balanced crystalloid intravenous solution (4 ml of normal saline)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post Operative Pain Scores
Time Frame: 5 days +/- 2 days
|
To assess if bilateral sphenopalatine nerve blocks can decrease post operative pain scores on a scale from 0-10, with a 0 meaning no pain and 10 meaning extreme pain.
Pain scores were assessed on post operative days 1, 3 and 5.
|
5 days +/- 2 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post Anesthesia Care Unit Duration
Time Frame: 60-180 minutes
|
To assess if bilateral sphenopalatine nerve blocks results in decreased post-anesthesia care unit observation time (assessed in minutes).
Patients are transferred to the post-anesthesia care units immediately following completion of surgery.
|
60-180 minutes
|
|
Text Message Survey Collection
Time Frame: 5 days post-operatively +/- 1 day
|
To assess the efficiency of SMS based survey for post-operative data collection
|
5 days post-operatively +/- 1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jeffrey D Johnson, MD, University of Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 12, 2023
Primary Completion (Actual)
February 28, 2025
Study Completion (Actual)
February 28, 2025
Study Registration Dates
First Submitted
November 4, 2022
First Submitted That Met QC Criteria
December 19, 2022
First Posted (Actual)
December 28, 2022
Study Record Updates
Last Update Posted (Actual)
April 27, 2026
Last Update Submitted That Met QC Criteria
April 6, 2026
Last Verified
August 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Postoperative Complications
- Pathologic Processes
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Pain, Postoperative
- Organic Chemicals
- Polycyclic Compounds
- Anilides
- Amides
- Aniline Compounds
- Amines
- Pregnadienes
- Pregnanes
- Steroids
- Fused-Ring Compounds
- Steroids, Fluorinated
- Pregnadienetriols
- Ropivacaine
- Dexamethasone
Other Study ID Numbers
- IRB202201279 -A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.